The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI
DOI:
https://doi.org/10.33393/grhta.2024.3045Keywords:
ABSSSI, Dalbavancin, Dehospitalization, Infection management, healthcare costsAbstract
Acute bacterial skin and skin structure infections (ABSSSIs) represent a common and costly healthcare burden, accounting for millions of annual infections and billions of dollars in healthcare expenditures. Dalbavancin is a long-acting glycopeptide antibiotic that has demonstrated efficacy and safety in the treatment of ABSSSIs. This review article will examine the efficacy of dalbavancin and focus on its impact on the hospital length of stay and costs associated with management of these infections.
Downloads
References
Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169-2179. https://doi.org/10.1056/NEJMoa1310480 PMID:24897082 DOI: https://doi.org/10.1056/NEJMoa1310480
Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545-551. https://doi.org/10.1093/cid/civ982 PMID:26611777 DOI: https://doi.org/10.1093/cid/civ982
Rappo U, Gonzalez PL, Puttagunta S, et al. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections. J Glob Antimicrob Resist. 2019;17:60-65. https://doi.org/10.1016/j.jgar.2019.02.007 PMID:30797084 DOI: https://doi.org/10.1016/j.jgar.2019.02.007
Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW. Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs. Drugs Context. 2018;7:212559. https://doi.org/10.7573/dic.212559 PMID:30574170 DOI: https://doi.org/10.7573/dic.212559
Nadipelly J, Raghunath P, Kothapalli J. Efficacy of dalbavancin and telavancin in the treatment of acute bacterial skin and skin structure infections. (Bucur). 2018;13(3):208-212. https://doi.org/10.26574%2Fmaedica.2018.13.3.208 PMID:3056870
Durante-Mangoni E, Gambardella M, Iula VD, et al. Current trends in the real-life use of dalbavancin: report of a study panel. Int J Antimicrob Agents. 2020;56(4):106107. https://doi.org/10.1016/j.ijantimicag.2020.106107 PMID:32721599 DOI: https://doi.org/10.1016/j.ijantimicag.2020.106107
Bosso JA, Casapao AM, Edwards J, et al. Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion. Hosp Pract (1995). 2016 Oct;44(4):183-189. https://doi.org/10.1080/21548331.2016.1230466 PMID:27598313 DOI: https://doi.org/10.1080/21548331.2016.1230466
Bai F, Mazzitelli M, Silvola S, et al. Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals. JAC Antimicrob Resist. 2023;5(2):dlad044. https://doi.org/10.1093/jacamr/dlad044 PMID:37090914 DOI: https://doi.org/10.1093/jacamr/dlad044
Poliseno M, Bavaro DF, Brindicci G, et al. Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different gram-positive bacterial infections. Clin Drug Investig. 2021;41(5):437-448. https://doi.org/10.1007/s40261-021-01028-3 PMID:33884583 DOI: https://doi.org/10.1007/s40261-021-01028-3
Koziatek C, Mohan S, Caspers C, Swaminathan A, Swartz J. Experience with dalbavancin for cellulitis in the emergency department and emergency observation unit. Am J Emerg Med. 2018;36(7):1312-1314. https://doi.org/10.1016/j.ajem.2017.11.037 PMID:29157791 DOI: https://doi.org/10.1016/j.ajem.2017.11.037
Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210-214. https://doi.org/10.1016/j.ijid.2019.02.013 PMID:30794940 DOI: https://doi.org/10.1016/j.ijid.2019.02.013
Tobudic S, Forstner C, Burgmann H, et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection. 2019;47(6):1013-1020. https://doi.org/10.1007/s15010-019-01354-x PMID:31520397 DOI: https://doi.org/10.1007/s15010-019-01354-x
Arrieta-Loitegui M, Caro-Teller JM, Ortiz-Pérez S, López-Medrano F, San Juan-Garrido R, Ferrari-Piquero JM. Effectiveness, safety and cost analysis of dalbavancin in clinical practice. Eur J Hosp Pharm Sci Pract. 2022;29(1):55-58. https://doi.org/10.1136/ejhpharm-2020-002315 PMID:33020060 DOI: https://doi.org/10.1136/ejhpharm-2020-002315
Dolan A, Kuge E, Bremmer E, Dietrich T, Santarelli A, Ashurst J. Real world utilization of Dalbavancin at a rural community emergency department. Am J Emerg Med. 2022;54:253-256. https://doi.org/10.1016/j.ajem.2022.02.006 PMID:35190304 DOI: https://doi.org/10.1016/j.ajem.2022.02.006
Simonetti O, Rizzetto G, Molinelli E, Cirioni O, Offidani A. Review: a safety profile of dalbavancin for on- and off-label utilization. Ther Clin Risk Manag. 2021;17:223-232. https://doi.org/10.2147/TCRM.S271445 PMID:33790563 DOI: https://doi.org/10.2147/TCRM.S271445
Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S. Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf. 2016;39(2):147-157. https://doi.org/10.1007/s40264-015-0374-9 PMID:26715497 DOI: https://doi.org/10.1007/s40264-015-0374-9
McCarthy MW, Keyloun KR, Gillard P, et al. Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial. Infect Dis Ther. 2020;9(1):53-67. https://doi.org/10.1007/s40121-019-00275-4 PMID:31713130 DOI: https://doi.org/10.1007/s40121-019-00275-4
Agarwal R, Bartsch SM, Kelly BJ, et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018;24(4):361-368. https://doi.org/10.1016/j.cmi.2017.08.028 PMID:28882727 DOI: https://doi.org/10.1016/j.cmi.2017.08.028
Marcellusi A, Viti R, Sciattella P, et al. Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries. Expert Rev Pharmacoecon Outcomes Res. 2019;19(5):581-599. https://doi.org/10.1080/14737167.2019.1569516 PMID:30714834 DOI: https://doi.org/10.1080/14737167.2019.1569516
Marcellusi A, Bini C, Andreoni M, et al. Budget impact analysis of dalbavancin in the treatment of acute bacterial skin and skin structure infections in three European countries. Clin Drug Investig. 2020;40(4):305-318. https://doi.org/10.1007/s40261-020-00891-w PMID:32034687 DOI: https://doi.org/10.1007/s40261-020-00891-w
Bouza E, Valerio M, Soriano A, et al; DALBUSE Study Group (Dalbavancina: Estudio de su uso clinico en España). Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51(4):571-577. https://doi.org/10.1016/j.ijantimicag.2017.11.008 PMID:29180276 DOI: https://doi.org/10.1016/j.ijantimicag.2017.11.008
Streifel AC, Sikka MK, Bowen CD, Lewis JS II. Dalbavancin use in an academic medical centre and associated cost savings. Int J Antimicrob Agents. 2019;54(5):652-654. https://doi.org/10.1016/j.ijantimicag.2019.08.007 PMID:31398481 DOI: https://doi.org/10.1016/j.ijantimicag.2019.08.007
Papavramidis T, Gentile I, Cattelan AM, et al. REDS study: retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI. Int J Antimicrob Agents. 2023 Apr;61(4):106746. https://doi.org/10.1016/j.ijantimicag.2023.106746 PMID:36758778 DOI: https://doi.org/10.1016/j.ijantimicag.2023.106746
Kaiser Family Foundation. Hospital adjusted expenses per inpatient day by ownership. 2022. https://www.kff.org/health-costs/state-indicator/expenses-per-inpatient-day-by-ownership/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22. Accessed February 2024.
Ektare V, Khachatryan A, Xue M, Dunne M, Johnson K, Stephens J. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. J Med Econ. 2015;18(12):1092-1101. https://doi.org/10.3111/13696998.2015.1078339 PMID:26368787 DOI: https://doi.org/10.3111/13696998.2015.1078339
Talan DA, Mower WR, Lovecchio FA, et al. Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections. Acad Emerg Med. 2021;28(10):1108-1117. https://doi.org/10.1111/acem.14258 PMID:33780567 DOI: https://doi.org/10.1111/acem.14258
Oliva A, Carbonara S, Cianci V, et al. Direct or early discharge of acute bacterial skin and skin structure infection patients from the emergency department/unit: place in therapy of dalbavancin. Expert Rev Anti Infect Ther. 2023;21(7):703-721. https://doi.org/10.1080/14787210.2023.2214727 PMID:37227028 DOI: https://doi.org/10.1080/14787210.2023.2214727
Wilke M, Worf K, Preisendörfer B, Heinlein W, Kast T, Bodmann KF. Potential savings through single-dose intravenous dalbavancin in long-term MRSA infection treatment – a health economic analysis using German DRG data. GMS Infect Dis. 2019;7:Doc03. https://doi.org/10.3205/id000043 PMID: 31728264
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to Global & Regional Health Technology Assessment agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.
Accepted 2024-04-29
Published 2024-07-29
